TeleRanked

Run a telehealth clinic? Claim your profile on TeleRanked.

Access

Telehealth Study at ObesityWeek 2026: GLP-1 Obesity Drugs Are Almost Never Covered Without Prior Authorization, and a Third of Initial Requests Are Denied

A late-breaking abstract presented at ObesityWeek 2026 found that among clinically eligible, commercially insured adults, GLP-1 obesity drugs were covered without prior authorization in only 3.7 percent of semaglutide and 2.8 percent of tirzepatide benefit checks, and 35.7 percent of 69,462 initial prior authorization requests were denied, most often because the plan excluded the drug. The data came from a telehealth platform, and the findings are a conference abstract, not a peer reviewed study.

The TeleRanked Editors·Updated November 17, 2026·8 min read

Quick answer

At ObesityWeek 2026 (November 14 to 17, National Harbor, Maryland), researchers including Ro's director of real world evidence reported that among clinically eligible, commercially insured adults, GLP-1 weight-loss drugs were covered without prior authorization in only 3.7 percent of semaglutide and 2.8 percent of tirzepatide benefit checks. Of 69,462 patients whose prescribers submitted an initial prior authorization to start treatment, 53.2 percent were approved and 35.7 percent were denied, with roughly half of denials (51.1 percent) attributed to the plan excluding the drug or limiting coverage. The results are a late-breaking conference abstract, not a peer reviewed study, and cover only commercially insured adults on one telehealth platform.

Key takeaways

  • →Coverage without prior authorization was rare: across about 225,000 benefit verifications, only 3.7 percent of semaglutide and 2.8 percent of tirzepatide checks showed coverage with no prior authorization required.
  • →Among 69,462 patients whose prescribers submitted an initial prior authorization to begin treatment, 53.2 percent were approved, 35.7 percent were denied, and 11.2 percent had an unknown outcome.
  • →Denials were driven by coverage design, not mostly by patients: 51.1 percent of denials cited plan exclusions or coverage limitations, 24.7 percent cited unmet clinical eligibility criteria, and 12.7 percent cited unmet therapy requirements such as a required prior medication trial.
  • →Patients with a BMI of 27.0 to 29.9 plus an obesity-related condition had the highest denial rate at 38.7 percent, and outcomes varied more by payer, pharmacy benefit manager, and region than by patient demographics or clinical characteristics.
  • →The analysis is a late-breaking ObesityWeek 2026 abstract, not peer reviewed, and is limited to commercially insured adults aged 18 to 63 on a single telehealth platform; it does not cover Medicare, Medicaid, or the uninsured.

Prescribing a GLP-1 drug through a telehealth visit is one thing. Getting a commercial health plan to pay for it is another. A late-breaking study presented at ObesityWeek 2026, The Obesity Society's annual meeting held November 14 to 17 in National Harbor, Maryland, puts hard numbers on that gap for people seeking GLP-1 weight-loss medications. Drawing on deidentified clinical and insurance data from a telehealth platform, the researchers found that for clinically eligible, commercially insured adults, coverage without a prior authorization was the rare exception, and more than a third of the initial requests to start treatment were denied.

What the study looked at

The abstract, titled 'Clinical eligibility and coverage gaps for GLP-1-based receptor agonists in patients with obesity,' was authored by Broffman, Smith, Manalac, and colleagues. The lead author, Lauren Broffman, is director of real world evidence at Ro, a direct-to-patient telehealth company that has presented coverage and prior authorization research at past Obesity Society meetings. The analysis used deidentified clinical and insurance data from a telehealth platform and focused on a defined eligible group: commercially insured adults aged 18 to 63 with a body mass index of 30 or higher, or a BMI of 27.0 to 29.9 with at least one obesity-related condition.

The team examined two steps of the coverage process over benefit verifications completed between January 1 and September 30, 2025. First, insurance benefit checks for a random sample of about 225,000 patients, to see whether a plan covered semaglutide or tirzepatide and whether it required prior authorization. Second, the outcomes of initial prior authorization submissions for 69,462 patients whose prescribers tried to start them on treatment.

Coverage without prior authorization is rare

On the benefit verification side, very few plans covered a GLP-1 obesity drug outright. Coverage with no prior authorization required reached only 3.7 percent of checks for semaglutide and 2.8 percent for tirzepatide. Coverage that was available but gated behind a prior authorization was far more common, at 35.7 percent for semaglutide and 31.1 percent for tirzepatide. For 27.0 percent of checks the coverage status came back indeterminate. In short, when these plans paid at all, they almost always required a prior authorization first.

More than a third of initial requests were denied

Among the 69,462 patients whose prescribers submitted an initial prior authorization to begin treatment, the outcomes split three ways: 53.2 percent were approved, 35.7 percent were denied, and 11.2 percent had an outcome the data could not confirm. A denial at this stage does not necessarily end the process, because plans allow appeals and resubmissions, but it is a barrier between a prescribed drug and a filled prescription.

Why requests were denied

The abstract grouped the reasons recorded for denials. The largest share pointed to how the benefit itself was designed rather than to anything about the individual patient:

  • Plan exclusions or coverage limitations: 51.1 percent of denials. The plan did not cover obesity drugs, or capped or restricted that coverage.
  • Unmet clinical eligibility criteria: 24.7 percent. The request did not satisfy the plan's BMI, diagnosis, or comorbidity rules.
  • Unmet therapy requirements: 12.7 percent. The plan required something first, such as a documented trial of another medication, a form of step therapy.

Who faced the most denials

Denial rates were not even across patients. The group with a BMI of 27.0 to 29.9 plus at least one obesity-related condition had the highest denial rate of any BMI band at 38.7 percent, and 41.7 percent of those denials were attributed to unmet clinical eligibility criteria. At the other end, among patients with a BMI of 40 or higher, 56.7 percent of denials were tied to plan exclusions or coverage limitations rather than eligibility. The researchers reported that outcomes varied more by payer, pharmacy benefit manager, and region than by patients' demographics or measured clinical characteristics, which points at plan design as the main lever.

Part of a wider denial trend

The ObesityWeek findings land alongside a peer reviewed analysis of insurance denials more broadly. In JAMA, Joseph F. Levy of the Johns Hopkins Bloomberg School of Public Health and colleagues studied formulary-related rejections of single-source branded drugs and found that the share of first fill attempts rejected for a formulary exclusion or utilization management rose from 24.3 percent in 2018 to 40.7 percent in 2024, about 32 percent across the period. Reporting on that study, the trade publication PharmaVoice noted that for weight-loss drugs specifically, payers approved the incretin class on the first attempt only 14.8 percent of the time. The Levy analysis covered branded drugs generally, not just obesity medicines, but it tracks with what the telehealth data show: coverage for these treatments is increasingly conditional.

What this means for telehealth weight-loss patients

For people pursuing GLP-1 treatment through a virtual clinic, the practical takeaway is that a prescription is rarely the end of the story. On these commercial plans, getting the drug covered usually meant clearing a prior authorization, and about one in three initial requests did not clear it on the first try, most often because the plan excluded or limited obesity-drug coverage rather than because of the patient. Because the deciding factor was so often the plan and its pharmacy benefit manager, two clinically similar patients can get different answers based on their coverage. People who are denied can ask their prescriber and plan about appeals, step-therapy documentation, or covered alternatives, and some turn to cash-pay options. This article is general information about a research presentation and is not medical or legal advice; decisions about treatment and coverage should be made with a licensed clinician and your own health plan.

Limits of the analysis

Several limits bound how far these numbers travel. The study is a late-breaking conference abstract, not a peer reviewed publication, so its methods and figures have not been through journal review and could be refined before any full paper. It covers only commercially insured adults aged 18 to 63 on a single telehealth platform, so it says nothing about Medicare, Medicaid, or uninsured patients, whose coverage rules differ. The benefit verification step returned an indeterminate result 27.0 percent of the time, and 11.2 percent of prior authorization outcomes were unknown, so the true picture is partly obscured. And the data is a cross-sectional snapshot of early-to-mid 2025; coverage policies change, and later periods could look different.

Frequently asked questions

Are GLP-1 weight-loss drugs usually covered by insurance without prior authorization?+

Rarely, according to this study. Across about 225,000 benefit checks for clinically eligible, commercially insured adults, only 3.7 percent of semaglutide and 2.8 percent of tirzepatide checks showed coverage with no prior authorization required. When these plans covered the drug at all, they almost always required a prior authorization first.

How often were prior authorization requests denied?+

Among 69,462 patients whose prescribers submitted an initial prior authorization to start treatment, 53.2 percent were approved, 35.7 percent were denied, and 11.2 percent had an unknown outcome. A denial is not necessarily final, since plans allow appeals and resubmissions.

Why were the requests denied?+

The most common recorded reason was plan design: 51.1 percent of denials cited plan exclusions or coverage limitations. Another 24.7 percent cited unmet clinical eligibility criteria such as BMI or diagnosis rules, and 12.7 percent cited unmet therapy requirements like a required prior trial of another medication.

Does this study apply to Medicare or Medicaid patients?+

No. The analysis was limited to commercially insured adults aged 18 to 63. It does not describe coverage or denial rates under Medicare, Medicaid, or for uninsured patients, where the rules are different.

Is this a peer reviewed study?+

No. It is a late-breaking abstract presented at ObesityWeek 2026, The Obesity Society's annual meeting held November 14 to 17, 2026, in National Harbor, Maryland. Conference abstracts have not been through full journal peer review, so the figures could change before any complete publication.

What can a patient do if a GLP-1 request is denied?+

This is general information, not medical or legal advice. In general, patients who are denied can ask their prescriber and health plan about the appeals process, about documenting any step-therapy requirements, and about covered alternatives; some also consider cash-pay options. The right path depends on your specific plan and clinical situation, so discuss it with a licensed clinician and your insurer.

Sources

  1. 1.ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs · The American Journal of Managed Care
  2. 2.Ro to Present Eight Research Abstracts at ObesityWeek 2025 (Lauren Broffman, Director of Real World Evidence; coverage and eligibility research) · Ro
  3. 3.Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States (Levy et al., JAMA, July 9, 2026) · JAMA
  4. 4.Brand-name drug denials are surging, especially for weight loss · PharmaVoice

Related